PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24451154-14	2014	In a PIK3CA-mutant HER2+ xenograft, PI3K inhibition with BKM120 in combination with lapatinib and trastuzumab was required to achieve tumor regression.	NVP-BKM120	57-63	erb-b2 receptor tyrosine kinase 2	Mus musculus	19-23	
28396358-2	2017	We previously showed that HER2+/PIK3CAH1047R transgenic mammary tumors are resistant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib (TPB).	NVP-BKM120	165-175	erb-b2 receptor tyrosine kinase 2	Mus musculus	26-30	
30705430-2	2019	The sentence should read "In mouse mammary tumour models, increased collagen levels and increased beta1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies164."	NVP-BKM120	321-331	erb-b2 receptor tyrosine kinase 2	Mus musculus	250-254